743-P: Efficacy and Safety of VCT220 in Chinese Adults with Overweight or Obesity

Le résumé fourni par la source

Introduction and Objective: To investigate the efficacy, safety, and tolerability of VCT220, a novel oral, small molecule once-daily glucagon-like peptide-1 receptor agonist, in Chinese nondiabetic adults with overweight or obesity. Methods: In this double-blind phase 2 randomized study, 250 Chinese adults with a BMI ≥28 kg/m2, or 24-28 kg/m2 accompanied by at least one obesity-related comorbidity were randomized 3:1 to 80mg, 120 mg, 160mg cohort to receive VCT220 or matching placebo. 160mg cohort was further divided (1:1)into fast or slow titration group. Primary endpoint was percentage change from baseline to week 16 in body weight(BW). Results: At baseline, mean BW was 91.76 kg, BMI was 32.03 kg/m2, and 93.6% of participants had a BMI ≥28 kg/m2. At week 16, mean percentage change in BW, the percentage of participants achieving ≥5%, or ≥10% weight loss target, mean change in waist circumference (WC) and blood pressure (BP) were significantly greater with all VCT220 doses vs placebo (Figure). Most commonly reported AEs were GI-related and mild to moderate in severity, with 98.0% of participants demonstrating good compliance. No drug related serious AEs was reported. Conclusion: This study showed VCT220 was safe and led to robust and clinically meaningful BW reduction and improvements in cardiac risk factors including BP and WC. These findings support further development of VCT220 as a oral treatment option for weight management. Disclosure L. Ji: None. L. Gao: Research Support; Sciwind Biosciences. C. Meng: None. X. Zhang: None. J. Huang: Employee; Suzhou Vincentage Pharma Co., Ltd. B. Li: None.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.